Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Even at lower BMIs, many South Asians carry more visceral (belly) fat compared to others. A commonly recognized stereotype—the combination of thin limbs and a prominent belly—reflects this ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Walt Disney Co. jumped more than 6% in premarket after the entertainment behemoth easily beat Wall Street’s profit targets ...

More importantly, the nut group -but not the high-carb group - showed increased expression of genes connected to breaking down fat cells, helping HDL cholesterol remove "bad" cholesterol, and reducing ...

Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater ...